EU Approves Aurobindo Pharma's Dyrupeg: New Pegfilgrastim Biosimilar for Chemotherapy Patients
核心洞察
The European Commission has granted marketing authorization for Dyrupeg™, a pegylated filgrastim biosimilar developed by CuraTeQ Biologics (搜索), a subsidiary of Aurobindo Pharma.
Dyrupeg™ is indicated for reducing neutropenia (搜索) duration and febrile neutropenia (搜索) incidence in adult cancer patients undergoing cytotoxic chemotherapy, offering a cost-effective alternative to existing treatments.
The approval follows a positive recommendation from the European Medicines Agency (搜索)'s Committee for Medicinal Products for Human Use (CHMP) in January 2025, marking a significant expansion of Aurobindo's biosimilar portfolio in Europe.
CuraTeQ Biologics (搜索), a wholly owned step-down subsidiary of Aurobindo Pharma, has received European Commission (EC) marketing authorization for Dyrupeg™, a pegylated filgrastim biosimilar, for use across the European Union. The approval, announced on April 5, 2025, represents a significant milestone in Aurobindo's strategy to expand its biosimilar portfolio in the European market.
The authorization follows a positive recommendation from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (搜索) (EMA) in January 2025, which endorsed the biosimilar's safety and efficacy profile.
Clinical Application and Formulation
Dyrupeg™ is specifically indicated for reducing the duration of neutropenia (搜索) and the incidence of febrile neutropenia (搜索) in adult patients undergoing cytotoxic chemotherapy for malignancies, with exceptions for chronic myeloid leukemia (搜索) and myelodysplastic syndromes (搜索). The medication will be available as a 6 mg solution for injection in prefilled syringes, designed for convenient administration.
Neutropenia (搜索), characterized by abnormally low levels of neutrophils (a type of white blood cell), is a common and potentially serious side effect of chemotherapy that can leave patients vulnerable to infections. By stimulating neutrophil production, pegfilgrastim helps maintain patients' immune defenses during cancer treatment.
Strategic Importance for Aurobindo
"This authorization represents a key advancement in our biologics strategy," Aurobindo Pharma stated in their exchange filing. The approval enables CuraTeQ Biologics (搜索) to market Dyrupeg™ throughout EU member states, providing cancer patients with a cost-effective alternative to existing pegfilgrastim products.
The development aligns with Aurobindo's broader mission to deliver high-quality, affordable healthcare solutions globally, particularly in the growing biosimilars market.
About CuraTeQ Biologics
CuraTeQ Biologics (搜索), headquartered in Hyderabad, India, focuses on developing biosimilars for cancer and autoimmune disease treatment. The company's pipeline includes fourteen biosimilars primarily targeting immunology and oncology. CuraTeQ possesses comprehensive capabilities spanning from bulk drug substance production to fill-finish and packaging operations.
Aurobindo's Growing Pharmaceutical Presence
Aurobindo Pharma operates 29 manufacturing and packaging facilities approved by major regulatory agencies worldwide, including the USFDA, UK MHRA, EDQM, Japan PMDA, WHO, Health Canada, South Africa MCC, and Brazil ANVISA. The company's diverse product portfolio encompasses seven major therapeutic areas: CNS, Anti-Retroviral, CVS, Antibiotics, Gastroenterological, Anti-Diabetics, and Anti-Allergic medications.
This latest approval strengthens Aurobindo's position in the competitive biosimilars market, where providing more affordable alternatives to expensive biologic drugs has become increasingly important for healthcare systems seeking to manage costs while maintaining quality patient care.